ArticleHealth economics review2026
Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1.
Kun Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.